Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 108, Issue , 2016, Pages 235-252

  Doktorovová, Slavomira ^a   Kovačević, Andjelka B ^a   Garcia, Maria L ^b   Souto, Eliana B ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Biocompatibility; In vivo and in vitro data; Nanotoxicology; Preclinical data; Safety; SLN NLC

Indexed keywords

ADAPALENE; AMPHOTERICIN B; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CELECOXIB; CYCLOSPORIN A; DIPHENCYPRONE; DOCETAXEL; FLURBIPROFEN; HALOFANTRINE; HUPERZINE A; IBUPROFEN; ISOTRETINOIN; LEVOFLOXACIN; MELOXICAM; METHOTREXATE; MINOXIDIL; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; OXYBENZONE; RETINOIC ACID; RETINOL PALMITATE; ROXITHROMYCIN; SOLID LIPID NANOPARTICLE; TACROLIMUS; TAMOXIFEN; TERBINAFINE; TOCOPHEROL; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; COLLOID; DRUG CARRIER; EXCIPIENT; LIPID; MUTAGENIC AGENT; NANOPARTICLE; SURFACTANT;

ARTICLE; BIOCHEMICAL ANALYSIS; CELL VIABILITY; CONTROLLED STUDY; CUTANEOUS DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; ENZYME ACTIVITY; ERYTHROCYTE COUNT; EVALUATION STUDY; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MALE; MOUSE; MUCOSAL DRUG ADMINISTRATION; NONHUMAN; PARENTERAL DRUG ADMINISTRATION; SKIN IRRITATION; THROMBOCYTE COUNT; ANIMAL; CELL SURVIVAL; CHEMISTRY; COLLOID; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EYE; IC50; METABOLISM; MUCOSA; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; SKIN; SURFACE PROPERTY; TOPICAL DRUG ADMINISTRATION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COLLOIDS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; EYE; HUMANS; INFUSIONS, PARENTERAL; INHIBITORY CONCENTRATION 50; LIPIDS; MICE; MUCOUS MEMBRANE; MUTAGENS; NANOPARTICLES; OXIDATIVE STRESS; SKIN; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS;

EID: 84993940162     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.08.001     Document Type: Article

References (181)

1. [1] Donaldson, K., Stone, V., Tran, C.L., Kreyling, W., Borm, P.J., Nanotoxicology. Occup. Environ. Med. 61 (2004), 727–728.
2. [2] Clift, M.J., Gehr, P., Rothen-Rutishauser, B., Nanotoxicology: a perspective and discussion of whether or not in vitro testing is a valid alternative. Arch. Toxicol. 85 (2011), 723–731.
3. [3] Müller, R.H., Gohla, S., Mäder, K., Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000), 161–177.
4. [4] Viladott, P.J.L.L., Delgado, G.R., Fernandez, B.A., Lipid Nanoparticle Capsules. 2013, Lipotec, S.A.
5. [5] Ghiani, S., Maiocchi, A., Brioschi, C., Visigalli, M., Cabella, C., Paramagnetic Solid Lipid Nanoparticles (Pslns) Containing Metal Amphiphilic Complexes for Mri. 2014, Bracco Imaging Spa.
6. [6] Herzog, B., Formulation of UV Absorbers by Incorporation in Solid Lipid Nanoparticles. 2006, Ciba Specialty Chemicals Corporation.
7. [7] Heppner, A., Hansen, P., Schumann, C., Solid Lipid Nanoparticles Containing a UV Filter Material Are Useful in Aqueous Dispersion Form as High Filter Content Sunscreen Compositions. 2001, Stada Arzneimittel Ag.
8. [8] Gaspar, R., Duncan, R., Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev. 61 (2009), 1220–1231.
9. [9] Doktorovova, S., Souto, E.B., Silva, A.M., Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro data. Eur. J. Pharm. Biopharm. 87 (2014), 1–18.
10. [10] Tran, T.H., Ramasamy, T., Truong, D.H., Shin, B.S., Choi, H.G., Yong, C.S., Kim, J.O., Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm. Res. 31 (2014), 1978–1988.
11. [11] Akanda, M.H., Rai, R., Slipper, I.J., Chowdhry, B.Z., Lamprou, D., Getti, G., Douroumis, D., Delivery of retinoic acid to LNCap human prostate cancer cells using solid lipid nanoparticles. Int. J. Pharm. 493 (2015), 161–171.
12. [12] Mohammadi Ghalaei, P., Varshosaz, J., Sadeghi Aliabadi, H., Evaluating cytotoxicity of hyaluronate targeted solid lipid nanoparticles of etoposide on SK-OV-3 cells. J. Drug Delivery, 2014 Article ID 746325.
13. [13] Parveen, R., Ahmad, F.J., Iqbal, Z., Samim, M., Ahmad, S., Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies. Drug Dev. Ind. Pharm. 40 (2014), 1206–1212.
14. [14] Jain, K., Sood, S., Gowthamarajan, K., Optimization of arthemether-loaded NLC for intranasal delivery using central composite design. Drug Delivery 22 (2014), 940–954.
15. [15] Koziara, J.M., Lockman, P.R., Allen, D.D., Mumper, R.J., Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 99 (2004), 259–269.
16. [16] Soddu, E., Rassu, G., Cossu, M., Giunchedi, P., Cerri, G., Gavini, E., The effect of formulative parameters on the size and physical stability of SLN based on ““green” components. Pharm. Dev. Technol. 21 (2016), 98–107.
17. [17] Kovacevic, A., Savic, S., Vuleta, G., Müller, R.H., Keck, C.M., Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int. J. Pharm. 406 (2011), 163–172.
18. [18] Kuo, Y.-C., Lee, I.H., Delivery of doxorubicin to glioblastoma multiforme in vitro using solid lipid nanoparticles with surface aprotinin and melanotransferrin antibody for enhanced chemotherapy. J. Taiwan Inst. Chem. Eng. 61 (2016), 32–45, 10.1016/j.jtice.2015.12.012 (in press).
19. [19] Bechinger, B., Lohner, K., Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim. Biophys. Acta (BBA) – Biomembranes 1758 (2006), 1529–1539.
20. [20] Lonez, C., Bessodes, M., Scherman, D., Vandenbranden, M., Escriou, V., Ruysschaert, J.M., Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways. Nanomedicine 10 (2014), 775–782.
21. [21] Xue, H.Y., Liu, S., Wong, H.L., Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond) 9 (2014), 295–312.
22. [22] Almeida, H., Lobão, P., Frigerio, C., Fonseca, J., Silva, R., Sousa Lobo, J.M., Amaral, M.H., Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen. Pharm. Dev. Technol., 2015, 1–14.
23. [23] Fangueiro, J.F., Andreani, T., Egea, M.A., Garcia, M.L., Souto, S.B., Silva, A.M., Souto, E.B., Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity. Int. J. Pharm. 461 (2014), 64–73.
24. [24] Yu, W., Liu, C., Ye, J., Zou, W., Zhang, N., Wenfang, X., Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery. Nanotechnology, 20, 2009, 215102.
25. [25] Hwang, T.-L., Aljuffali, I.A., Hung, C.-F., Chen, C.-H., Fang, J.-Y., The impact of cationic solid lipid nanoparticles on human neutrophil activation and formation of neutrophil extracellular traps NETs. Chem. Biol. Interact. 235 (2015), 106–114.
26. [26] Hwang, T.-L., Aljuffali, I.A., Lin, C.-F., Chang, Y.-T., Fang, J.-Y., Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. Int. J. Nanomed. 2015:9 (2015), 371–385.
27. [27] Gartziandia, O., Herrán, E., Pedraz, J.L., Carro, E., Igartua, M., Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf. B 134 (2015), 304–313.
28. [28] Üstündağ-Okur, N., Gökçe, E.H., Bozbıyık, D.İ., Eğrilmez, S., Ertan, G., Özer, Ö., Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. Expert Opin. Drug Delivery 12 (2015), 1791–1807.
29. [29] Hansraj, G.P., Singh, S.K., Kumar, P., Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential. Int. J. Biol. Macromol. 81 (2015), 467–476.
30. [30] Ramalingam, P., Ko, Y.T., Improved oral delivery of resveratrol from N -trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles. Colloids Surf. B 139 (2016), 52–61.
31. [31] Li, X., Bou-Chacra, N.A., Keck, C.M., Müller, R.H., Cationic lipid-free cationic nanoemulsions with dexamethasone acetate and polymyxin sulfate. Int. Symp. Control, 2015, Rel. Bioact. Mater 42, Edinburgh, Scotland.
32. [32] Gratton, S.E., Ropp, P.A., Pohlhaus, P.D., Luft, J.C., Madden, V.J., Napier, M.E., DeSimone, J.M., The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 105 (2008), 11613–11618.
33. [33] Lawlor, C., O'Sullivan, M.P., Sivadas, N., O'Leary, S., Gallagher, P.J., Keane, J., Cryan, S.A., The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages. Mol. Pharm. 8 (2011), 1100–1112.
34. [34] Hartmann, N.B., Jensen, K.A., Baun, A., Rasmussen, K., Rauscher, H., Tantra, R., Cupi, D., Gilliland, D., Pianella, F., Riego Sintes, J.M., Techniques and protocols for dispersing nanoparticle powders in aqueous media-is there a rationale for harmonization?. J. Toxicol. Environ. Health. Part B 18 (2015), 299–326.
35. [35] Müller, R.H., Rühl, D., Runge, S., Schulze-Forster, K., Mehnert, W., Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14 (1997), 458–462.
36. [36] Keck, C.M., Baisaeng, N., Durand, P., Prost, M., Meinke, M.C., Müller, R.H., Oil-enriched, ultra-small nanostructured lipid carriers (usNLC): a novel delivery system based on flip-flop structure. Int. J. Pharm. 477 (2014), 227–235.
37. [37] Singh, S., Singh, M., Tripathi, C.B., Arya, M., Saraf, S.A., Development and evaluation of ultra-small nanostructured lipid carriers: novel topical delivery system for athlete's foot. Drug Deliv. Translat. Res. 6 (2015), 38–47.
38. [38] Schubert, M.A., Müller-Goymann, C.C., Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm. 61 (2005), 77–86.
39. [39] Silva, A.H., Filippin-Monteiro, F.B., Mattei, B., Zanetti-Ramos, B.G., Creczynski-Pasa, T.n.B., In vitro biocompatibility of solid lipid nanoparticles. Sci. Total Environ. 432 (2012), 382–388.
40. [40] Kuo, Y.-C., Liang, C.-T., Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Colloids Surf. B 85 (2011), 131–137.
41. [41] Brugè, F., Damiani, E., Marcheggiani, F., Offerta, A., Puglia, C., Tiano, L., A comparative study on the possible cytotoxic effects of different nanostructured lipid carrier (NLC) compositions in human dermal fibroblasts. Int. J. Pharm. 495 (2015), 879–885.
42. [42] Weyenberg, W., Filev, P., Van den Plas, D., Vandervoort, J., De Smet, K., Sollie, P., Ludwig, A., Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int. J. Pharm. 337 (2007), 291–298.
43. [43] Sacchetti, F., Marraccini, C., D'Arca, D., Pelà, M., Pinetti, D., Maretti, E., Hanuskova, M., Iannuccelli, V., Costi, M.P., Leo, E., Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery. Colloids Surf. B 136 (2015), 346–354.
44. [44] Maretti, E., Rossi, T., Bondi, M., Croce, M.A., Hanuskova, M., Leo, E., Sacchetti, F., Iannuccelli, V., Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis. Int. J. Pharm. 462 (2014), 74–82.
45. [45] Genc, L., Kutlu, H.M., Guney, G., Vitamin B12-loaded solid lipid nanoparticles as a drug carrier in cancer therapy. Pharm. Dev. Technol. 20 (2015), 337–344.
46. [46] Sonawane, R., Harde, H., Katariya, M., Agrawal, S., Jain, S., Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert Opin. Drug Deliv. 11 (2014), 1833–1847.
47. [47] Dolatabadi, J.E.N., Hamishehkar, H., Eskandani, M., Valizadeh, H., Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf. B 117 (2014), 21–28.
48. [48] Bhushan, S., Kakkar, V., Pal, H.C., Mondhe, D.M., Kaur, I.P., The augmented anticancer potential of AP9-cd loaded solid lipid nanoparticles in Human leukemia Molt-4 cells and experimental tumor. Chem. Biol. Interact. 244 (2016), 84–93.
49. [49] Bruge, F., Damiani, E., Puglia, C., Offerta, A., Armeni, T., Littarru, G.P., Tiano, L., Nanostructured lipid carriers laded with Coq10: effect on human dermal fibroblasts under normal and UVA-mediated oxidative conditions. Int. J. Pharm. 455 (2013), 348–356.
50. [50] Eskandani, M., Nazemiyeh, H., Self-reporter shikonin-act-loaded solid lipid nanoparticle: formulation, physicochemical characterization and geno/cytotoxicity evaluation. Eur. J. Pharm. Sci. 59 (2014), 49–57.
51. [51] Lakkadwala, S., Nguyen, S., Lawrence, J., Nauli, S.M., Nesamony, J., Physico-chemical characterisation, cytotoxic activity, and biocompatibility studies of tamoxifen-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification method. J. Microencapsul. 31 (2014), 590–599.
52. [52] Negi, L.M., Talegaonkar, S., Jaggi, M., Verma, A.K., Verma, R., Dobhal, S., Kumar, V., Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies. Colloids Surf. B 123 (2014), 610–615.
53. [53] Jain, A., Kesharwani, P., Garg, N.K., Jain, A., Jain, S.A., Jain, A.K., Nirbhavane, P., Ghanghoria, R., Tyagi, R.K., Katare, O.P., Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin. Colloids Surf. B 134 (2015), 47–58.
54. [54] Doktorovová, S., Santos, D.L., Costa, I., Andreani, T., Souto, E.B., Silva, A.M., Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells. Int. J. Pharm. 471 (2014), 18–27.
55. [55] Vallianou, N.G., Evangelopoulos, A., Schizas, N., Kazazis, C., Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 35 (2015), 645–651.
56. [56] Kyadarkunte, A.Y., Patole, M.S., Pokharkar, V.B., Cellular interactions and photoprotective effects of idebenone-loaded nanostructured lipid carriers stabilized using PEG-free surfactant. Int. J. Pharm. 479 (2015), 77–87.
57. [57] Leonardi, A., Crasci’, L., Panico, A., Pignatello, R., Antioxidant activity of idebenone-loaded neutral and cationic solid–lipid nanoparticles. Pharm. Dev. Technol. 20 (2015), 716–723.
58. [58] Park, J.-H., Ban, S.-J., Ahmed, T., Choi, H.S., Yoon, H.-E., Yoon, J.-H., Choi, H.-K., Development of DH-I-180-3 loaded lipid nanoparticle for photodynamic therapy. Int. J. Pharm. 491 (2015), 393–401.
59. [59] Bondi, M., Ferraro, M., Di Vincenzo, S., Gerbino, S., Cavallaro, G., Giammona, G., Botto, C., Gjomarkaj, M., Pace, E., Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers. J. Nanobiotechnol., 12, 2014, 46.
60. [60] Nafee, N., Husari, A., Maurer, C.K., Lu, C., de Rossi, C., Steinbach, A., Hartmann, R.W., Lehr, C.-M., Schneider, M., Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J. Control. Release 192 (2014), 131–140.
61. [61] Kalhapure, R.S., Mocktar, C., Sikwal, D.R., Sonawane, S.J., Kathiravan, M.K., Skelton, A., Govender, T., Ion pairing with linoleic acid simultaneously enhances encapsulation efficiency and antibacterial activity of vancomycin in solid lipid nanoparticles. Colloids Surf. B 117 (2014), 303–311.
62. [62] Bonifácio, B.V., Ramos, M.A., da Silva, P.V., Negri, K.M., de Oliveira Lopes, É., de Souza, L.P., Vilegas, W., Pavan, F.R., Chorilli, M., Bauab, T.M., Nanostructured lipid system as a strategy to improve the anti-Candida albicans activity of Astronium sp. Int. J. Nanomed. 10 (2015), 5081–5092.
63. [63] Mendes, R.J., Castro, P.G., Doktorovova, S., Silva, A.M., Sampaio, A., Solid lipid nanoparticles affect leaf litter microbial colonizers and enzymatic activities in freshwater. 10th Iberian and 7th Iberoamerican Congress on Environmental Contamination and Toxicology Vila Real, Portugal, 2015.
64. [64] Paudel, K.S., Milewski, M., Swadley, C.L., Brogden, N.K., Ghosh, P., Stinchcomb, A.L., Challenges and opportunities in dermal/transdermal delivery. Therapeutic Delivery 1 (2010), 109–131.
65. [65] UN, United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS), in: UN New York and Geneva, 2009.
66. [66] FDA, Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route Guidance for Industry and Review Staff Good Review Practice, in: U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Rockville, Maryland, 2015.
67. [67] Castro, G.A., Coelho, A.L., Oliveira, C.A., Mahecha, G.A., Orefice, R.L., Ferreira, L.A., Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int. J. Pharm. 381 (2009), 77–83.
68. [68] Shah, K.A., Date, A.A., Joshi, M.D., Patravale, V.B., Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int. J. Pharm. 345 (2007), 163–171.
69. [69] Pople, P.V., Singh, K.K., Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int. J. Pharm. 398 (2010), 165–178.
70. [70] Mehnert, W., Mäder, K., Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev. 47 (2001), 165–196.
71. [71] Lippacher, A., Müller, R.H., Mäder, K., Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int. J. Pharm. 196 (2000), 227–230.
72. [72] Lippacher, A., Müller, R.H., Mäder, K., Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int. J. Pharm. 214 (2001), 9–12.
73. [73] Lippacher, A., Müller, R.H., Mäder, K., Semisolid SLN™ dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. Eur. J. Pharm. Biopharm. 53 (2002), 155–160.
74. [74] Lippacher, A., Müller, R.H., Mäder, K., Liquid and semisolid SLN™ dispersions for topical application: Rheological characterization. Eur. J. Pharm. Biopharm. 58 (2004), 561–567.
75. [75] Mitri, K., Shegokar, R., Gohla, S., Anselmi, C., Müller, R.H., Lipid nanocarriers for dermal delivery of lutein: Preparation, characterization, stability and performance. Int. J. Pharm. 414 (2011), 267–275.
76. [76] Schwarz, J.C., Weixelbaum, A., Pagitsch, E., Löw, M., Resch, G.P., Valenta, C., Nanocarriers for dermal drug delivery: influence of preparation method, carrier type and rheological properties. Int. J. Pharm. 437 (2012), 83–88.
77. [77] Kovačević, A.B., Müller, R.H., Savić, S.D., Vuleta, G.M., Keck, C.M., Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: preparation, characterization and physical stability investigation. Colloids Surf. A 444 (2014), 15–25.
78. [78] Keck, C.M., Kovačević, A., Müller, R.H., Savić, S., Vuleta, G., Milić, J., Formulation of solid lipid nanoparticles (SLN): the value of different alkyl polyglucoside surfactants. Int. J. Pharm. 474 (2014), 33–41.
79. [79] OECD, In vitro skin irritation: reconstructed human epidermis test method, OECD Guidelines for the testing of chemicals No 439 in, OECD, Paris, 2014.
80. [80] Faller, C., Bracher, M., Dami, N., Roguet, R., Predictive ability of reconstructed human epidermis equivalents for the assessment of skin irritation of cosmetics. Toxicol. In Vitro 16 (2002), 557–572.
81. [81] Welss, T., Basketter, D.A., Schröder, K.R., In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicol. in vitro 18 (2004), 231–243.
82. [82] Harde, H., Agrawal, A.K., Katariya, M., Kale, D., Jain, S., Development of a topical adapalene-solid lipid nanoparticle loaded gel with enhanced efficacy and improved skin tolerability. RSC Adv. 5 (2015), 43917–43929.
83. [83] Marcato, P.D., Caverzan, J., Rossi-Bergmann, B., Pinto, E.F., Machado, D., Silva, R.A., Justo, G.Z., Ferreira, C.V., Durán, N., Nanostructured polymer and lipid carriers for sunscreen. Biological effects and skin permeation. J. Nanosci. Nanotechnol. 11 (2011), 1880–1886.
84. [84] Aljuffali, I.A., Sung, C.T., Shen, F.M., Huang, C.T., Fang, J.Y., Squarticles as a lipid nanocarrier for delivering diphencyprone and minoxidil to hair follicles and human dermal papilla cells. AAPS J. 16 (2014), 140–150.
85. [85] Wosicka-Frackowiak, H., Cal, K., Stefanowska, J., Glowka, E., Nowacka, M., Struck-Lewicka, W., Govedarica, B., Pasikowska, M., Debowska, R., Jesionowski, T., Srcic, S., Markuszewski, M.J., Roxithromycin-loaded lipid nanoparticles for follicular targeting. Int. J. Pharm. 495 (2015), 807–815.
86. [86] Abla, M.J., Banga, A.K., Formulation of tocopherol nanocarriers and in vitro delivery into human skin. Int. J. Cosmet. Sci. 36 (2014), 239–246.
87. [87] Bhalekar, M., Upadhaya, P., Madgulkar, A., Formulation and evaluation of adapalene-loaded nanoparticulates for epidermal localization. Drug Deliv. Translat. Res. 5 (2015), 585–595.
88. [88] Castro, G.A., Oliveira, C.A., Mahecha, G.A., Ferreira, L.A., Comedolytic effect and reduced skin irritation of a new formulation of all-trans retinoic acid-loaded solid lipid nanoparticles for topical treatment of acne. Arch. Dermatol. Res. 303 (2011), 513–520.
89. [89] Butani, D., Yewale, C., Misra, A., Topical Amphotericin B solid lipid nanoparticles: design and development. Colloids Surf. B 139 (2016), 17–24.
90. [90] Lin, Y.-K., Huang, Z.-R., Zhuo, R.-Z., Fang, J.-Y., Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomed. 5 (2010), 117–128.
91. [91] Bikkad, M.L., Nathani, A.H., Mandlik, S.K., Shrotriya, S.N., Ranpise, N.S., Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery. J. Liposome Res. 24 (2014), 113–123.
92. [92] Patel, P.A., Patil, S.C., Kalaria, D.R., Kalia, Y.N., Patravale, V.B., Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int. J. Pharm. 446 (2013), 16–23.
93. [93] Raza, K., Singh, B., Singal, P., Wadhwa, S., Katare, O.P., Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf. B 105 (2013), 67–74.
94. [94] Khurana, S., Bedi, P.M., Jain, N.K., Preparation and evaluation of solid lipid nanoparticles based nanogel for dermal delivery of meloxicam. Chem. Phys. Lipids 175–176 (2013), 65–72.
95. [95] Clares, B., Calpena, A.C., Parra, A., Abrego, G., Alvarado, H., Fangueiro, J.F., Souto, E.B., Nanoemulsions (NEs), liposomes (LPs) and solid lipid nanoparticles (SLNs) for retinyl palmitate: effect on skin permeation. Int. J. Pharm. 473 (2014), 591–598.
96. [96] Pople, P.V., Singh, K.K., Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis-Part II: in vivo assessment of dermatopharmacokinetics, biodistribution and efficacy. Int. J. Pharm. 434 (2012), 70–79.
97. [97] Wavikar, P., Vavia, P., Nanolipidgel for enhanced skin deposition and improved antifungal activity. AAPS PharmSciTech 14 (2013), 222–233.
98. [98] Raza, K., Singh, B., Lohan, S., Sharma, G., Negi, P., Yachha, Y., Katare, O.P., Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int. J. Pharm. 456 (2013), 65–72.
99. [99] Mandawgade, S.D., Patravale, V.B., Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int. J. Pharm. 363 (2008), 132–138.
100. [100] Murphy, M., Carmichael, A.J., Transdermal drug delivery systems and skin sensitivity reactions. Am. J. Clin. Dermatol. 1 (2000), 361–368.
101. [101] Lehman, P.A., Slattery, J.T., Franz, T.J., Percutaneous absorption of retinoids: influence of vehicle, light exposure, and dose. J. Investigat. Dermatol. 91 (1988), 56–61.
102. [102] Nighland, M., Yusuf, M., Wisniewski, S., Huddleston, K., Nyirady, J., The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis 77 (2006), 313–316.
103. [103] Singh, J., Maibach, H.I., Transdermal delivery and cutaneous reactions. Kenneth, A.W., (eds.) Dermatological and Transdermal Formulations, 2002, Marcel Dekker Inc., New York, 529–548.
104. [104] Santos, C.M., Oliveira, R.B., Arantes, V.T., Caldeira, L.R., Oliveira, M.C., Egito, E.S.T., Ferreira, L.A.M., Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies. J. Biomed. Nanotechnol. 8 (2012), 322–329.
105. [105] Kleinberg, M., What is the current and future status of conventional amphotericin B?. Int. J. Antimicrob. Agents 27 (2006), 12–16.
106. [106] Walsh, T.J., Hiemenz, J.W., Seibel, N.L., Perfect, J.R., Horwith, G., Lee, L., Silber, J.L., DiNubile, M.J., Reboli, A., Bow, E., Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26 (1998), 1383–1396.
107. [107] Souto, E.B., Müller, R.H., Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Schäfer-Korting, M., (eds.) Handbook of Experimental Pharmacology Vol 197: Drug Delivery, 2010, Springer-Verlag, Berlin Heidelberg, 115–141.
108. [108] del Pozo-Rodríguez, A., Delgado, D., Gascón, A.R., Solinís, M.Á., Lipid nanoparticles as drug/gene delivery systems to the retina. J. Ocul. Pharmacol. Ther. 29 (2013), 173–188.
109. [109] Pignatello, R., Puglisi, G., Nanotechnology in ophthalmic drug delivery: a survey of recent developments and patenting activity. Recent Patents Nanomed. 1 (2011), 42–54.
110. [110] Li, J., Guo, X., Liu, Z., Okeke, C.I., Li, N., Zhao, H., Aggrey, M.O., Pan, W., Wu, T., Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies. Drug Dev. Ind. Pharm. 40 (2014), 980–987.
111. [111] Gokce, E.H., Sandri, G., Bonferoni, M.C., Rossi, S., Ferrari, F., Guneri, T., Caramella, C., Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int. J. Pharm. 364 (2008), 76–86.
112. [112] Lai, J.-Y., Biocompatibility of chemically cross-linked gelatin hydrogels for ophthalmic use. J. Mater. Sci. – Mater. Med. 21 (2010), 1899–1911.
113. [113] Draize, J.H., Woodard, G., Calvery, H.O., Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 82 (1944), 377–390.
114. [114] Hornof, M., Toropainen, E., Urtti, A., Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm. 60 (2005), 207–225.
115. [115] Leonardi, A., Bucolo, C., Romano, G.L., Platania, C.B., Drago, F., Puglisi, G., Pignatello, R., Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int. J. Pharm. 470 (2014), 133–140.
116. [116] Gokce, E.H., Sandri, G., Egrilmez, S., Bonferoni, M.C., Guneri, T., Caramella, C., Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr. Eye Res. 34 (2009), 996–1003.
117. [117] Araujo, J., Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., Souto, E.B., Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm. 393 (2010), 168–176.
118. [118] Gonzalez-Mira, E., Egea, M.A., Souto, E.B., Calpena, A.C., Garcia, M.L., Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology, 22, 2011, 045101.
119. [119] Shen, J., Sun, M., Ping, Q., Ying, Z., Liu, W., Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology, 21, 2010, 025101.
120. [120] Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., Souto, E.B., Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf. B 81 (2010), 412–421.
121. [121] Li, X., Nie, S.F., Kong, J., Li, N., Ju, C.Y., Pan, W.S., A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm. 363 (2008), 177–182.
122. [122] Baig, M.S., Ahad, A., Aslam, M., Imam, S.S., Aqil, M., Ali, A., Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: optimization, in vitro release, ocular tolerance, and antibacterial activity. Int. J. Biol. Macromol. 85 (2016), 258–270.
123. [123] Shen, J., Wang, Y., Ping, Q., Xiao, Y., Huang, X., Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J. Control. Release 137 (2009), 217–223.
124. [124] Luo, Q., Zhao, J., Zhang, X., Pan, W., Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int. J. Pharm. 403 (2011), 185–191.
125. [125] Kakkar, S., Karuppayil, S.M., Raut, J.S., Giansanti, F., Papucci, L., Schiavone, N., Kaur, I.P., Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole. Int. J. Pharm. 495 (2015), 276–289.
126. [126] Leonardi, A., Bucolo, C., Drago, F., Salomone, S., Pignatello, R., Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. Int. J. Pharm. 478 (2015), 180–186.
127. [127] Cavalli, R., Rosa Gasco, M., Chetoni, P., Burgalassi, S., Fabrizio Saettone, M., Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 238 (2002), 241–245.
128. [128] Araújo, J., Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., Souto, E.B., Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm. 393 (2010), 168–176.
129. [129] Klang, S., Abdulrazik, M., Benita, S., Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm. Dev. Technol. 5 (2000), 521–532.
130. [130] Kuwano, M., Ibuki, H., Morikawa, N., Ota, A., Kawashima, Y., Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm. Res. 19 (2002), 108–111.
131. [131] Başaran, E., Demirel, M., Sırmagül, B., Yazan, Y., Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J. Microencapsul. 27 (2010), 37–47.
132. [132] Shaikh, M.Y., Mars, J.S., Heaven, C.J., Prednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgery. J. Cataract Refract. Surg. 29 (2003), 2372–2377.
133. [133] Shete, H.K., Selkar, N., Vanage, G.R., Patravale, V.B., Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects. Int. J. Pharm. 468 (2014), 1–14.
134. [134] Ogbonna, J.D.N., Kenechukwu, F.C., Nwobi, C.S., Chibueze, O.S., Attama, A.A., Formulation, in vitro and in vivo evaluation of halofantrine-loaded solid lipid microparticles. Pharm. Dev. Technol. 20 (2015), 941–948.
135. [135] Rao, M.P., Manjunath, K., Bhagawati, S.T., Thippeswamy, B.S., Bixin loaded solid lipid nanoparticles for enhanced hepatoprotection – preparation, characterisation and in vivo evaluation. Int. J. Pharm. 473 (2014), 485–492.
136. [136] Kishore, N., Raja, M.D., Kumar, C.S., Dhanalekshmi, U., Srinivasan, R., Lipid carriers for delivery of celecoxib: in vitro, in vivo assessment of nanomedicine in rheumatoid arthritis. Eur. J. Lipid Sci. Technol. 118 (2016), 949–958, 10.1002/ejlt.201400658 in press.
137. [137] Paliwal, R., Paliwal, S.R., Agrawal, G.P., Vyas, S.P., Biomimetic solid lipid nanoparticles for oral bioavailability enhancement of low molecular weight heparin and its lipid conjugates: In vitro and in vivo evaluation. Mol. Pharm. 8 (2011), 1314–1321.
138. [138] Müller, R.H., Heinemann, S., Fat emulsions for parenteral nutrition II: Characterisation and physical long-term stability of Lipofundin. Clin. Nutr. 12 (1993), 298–309.
139. [139] Freitas, C., Muller, R.H., Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J. Microencapsul. 16 (1999), 59–71.
140. [140] Kasongo, K.W., Jansch, M., Muller, R.H., Walker, R.B., Evaluation of the in vitro differential protein adsorption patterns of didanosine-loaded nanostructured lipid carriers (NLCs) for potential targeting to the brain. J. Liposome Res. 21 (2011), 245–254.
141. [141] Huang, J.-Y., Lu, Y.-M., Wang, H., Liu, J., Liao, M.-H., Hong, L.-J., Tao, R.-R., Ahmed, M.M., Liu, P., Liu, S.-S., Fukunaga, K., Du, Y.-Z., Han, F., The effect of lipid nanoparticle PEGylation on neuroinflammatory response in mouse brain. Biomaterials 34 (2013), 7960–7970.
142. [142] Blasi, P., Schoubben, A., Traina, G., Manfroni, G., Barberini, L., Alberti, P.F., Cirotto, C., Ricci, M., Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. Int. J. Pharmaceutics 454 (2013), 316–323.
143. [143] Jain, A., Agarwal, A., Majumder, S., Lariya, N., Khaya, A., Agrawal, H., Majumdar, S., Agrawal, G.P., Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J. Control. Release 148 (2010), 359–367.
144. [144] Weyhers, H., Ehlers, S., Hahn, H., Souto, E.B., Müller, R.H., Solid lipid nanoparticles (SLN) – effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 61 (2006), 539–544.
145. [145] Liu, D., Liu, Z., Wang, L., Zhang, C., Zhang, N., Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf. B 85 (2011), 262–269.
146. [146] Sloat, B.R., Sandoval, M.A., Li, D., Chung, W.-G., Lansakara-P, D.S.P., Proteau, P.J., Kiguchi, K., DiGiovanni, J., Cui, Z., In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int. J. Pharm. 409 (2011), 278–288.
147. [147] Nayak, A.P., Patankar, S., Madhusudhan, B., Murthy, R.S.R., Souto, E.B., Arthemether-loaded lipid nanoparticles produced by modified thin-film hydration: pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur. J. Pharm. Sci. 40 (2010), 448–455.
148. [148] Gao, Y., Yang, R., Zhang, Z., Chen, L., Sun, Z., Li, Y., Solid lipid nanoparticles reduce systemic toxicity of docetaxel: performance and mechanism in animal. Nanotoxicology 5 (2011), 636–649.
149. [149] Xu, Z.H., Chen, L.L., Gu, W.W., Gao, Y., Lin, L.P., Zhang, Z.W., Xi, Y., Li, Y.P., The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30 (2009), 226–232.
150. [150] Dong, X., Wang, W., Qu, H., Han, D., Zheng, J., Sun, G., Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo. Drug Delivery, 2015, 1–5.
151. [151] Yang, X.-Y., Li, Y.-X., Li, M., Zhang, L., Feng, L.-X., Zhang, N., Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett. 334 (2013), 338–345.
152. [152] Xu, P., Yin, Q., Shen, J., Chen, L., Yu, H., Zhang, Z., Li, Y., Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS. Int. J. Pharm. 454 (2013), 21–30.
153. [153] Han, C., Qi, C.M., Zhao, B.K., Cao, J., Xie, S.Y., Wang, S.L., Zhou, W.Z., Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J. Vet. Pharmacol. Ther. 32 (2009), 116–123.
154. [154] Silva, A.H., Locatelli, C., Fillipin-Monteiro, F.B., Zanetti-Ramos, B.G., Conte, A., Creczynski-Pasa, T.B., Solid lipid nanoparticles induced hematological changes and inflammatory response in mice. Nanotoxicology, 2014, 1–8.
155. [155] Sanna, V., Kirschvink, N., Gustin, P., Gavini, E., Roland, I., Delattre, L., Evrard, B., Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech 5 (2004), 17–23.
156. [156] Nassimi, M., Schleh, C., Lauenstein, H.D., Hussein, R., Hoymann, H.G., Koch, W., Pohlmann, G., Krug, N., Sewald, K., Rittinghausen, S., Braun, A., Müller-Goymann, C., A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 75 (2010), 107–116.
157. [157] Madane, R.G., Mahajan, H.S., Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Delivery, 2015, 1–9.
158. [158] Gabal, Y.M., Kamel, A.O., Sammour, O.A., Elshafeey, A.H., Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int. J. Pharm. 473 (2014), 442–457.
159. [159] Battaglia, L., Gallarate, M., Peira, E., Chirio, D., Solazzi, I., Giordano, S.M.A., Gigliotti, C.L., Riganti, C., Dianzani, C., Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies. Nanotechnology, 26, 2015, 255102.
160. [160] Wang, L., Luo, Q., Lin, T., Li, R., Zhu, T., Zhou, K., Ji, Z., Song, J., Jia, B., Zhang, C., Chen, W., Zhu, G., PEGylated nanostructured lipid carriers (PEG–NLC) as a novel drug delivery system for biochanin A. Drug Dev. Ind. Pharm. 41 (2015), 1204–1212.
161. [161] Ramalingam, P., Ko, Y., Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm. Res. 32 (2015), 389–402.
162. [162] Chen, Y., Yang, X., Zhao, L., Almasy, L., Garamus, V.M., Willumeit, R., Zou, A., Preparation and Characterization of a nanostructured lipid carrier for a poorly soluble drug. Coll Surfaces A: Phys Eng Aspects 455 (2014), 36–43.
163. [163] Yuan, Q., Han, J., Cong, W.S., Ge, Y., Ma, D.D., Dai, Z.X., YP, Li, XL, B., Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int. J. Nanomed. 9 (2014), 4829–4846.
164. [164] Ghalaei, P.M., Varshosaz, J., Aliabadi, H.S., Evaluating cytotoxicity of hyaluronate targeted solid lipid nanoparticles of etoposide on SK-OV-3 cells. J. Drug Delivery, 2014 Article ID 746325.
165. [165] Guo, T., Zhang, Y., Zhao, J., Zhu, C., Feng, N., Nanostructured lipid carriers for percutaneous administration of alkaloids isolated from Aconitum sinomontanum. J. Nanobiotechnol., 13, 2015.
166. [166] Laserra, S., Basit, A., Sozio, P., Marinelli, L., Fornasari, E., Cacciatore, I., Ciulla, M., Türkez, H., Geyikoglu, F., Stefano, A.D., Solid lipid nanoparticles loaded with lipoyl–memantine codrug: preparation and characterization. Int. J. Pharm. 485 (2015), 183–191.
167. [167] Miao, J., Du, Y., Yuan, H., Zhang, X., Li, Q., Rao, Y., Zhao, M., Hu, F., Improved cytotoxicity of paclitaxel loaded in nanosized lipid carriers by intracellular delivery. J. Nanopart. Res. 17 (2015), 1–13.
168. [168] Baek, J.-S., Cho, C.-W., Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles. Int. J. Pharm. 478 (2015), 617–624.
169. [169] Chirio, D., Gallarate, M., Peira, E., Battaglia, L., Muntoni, E., Riganti, C., Biasibetti, E., Capucchio, M.T., Valazza, A., Panciani, P., Lanotte, M., Annovazzi, L., Caldera, V., Mellai, M., Filice, G., Corona, S., Schiffer, D., Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. Eur. J. Pharm. Biopharm. 88 (2014), 746–758.
170. [170] Gaspar, D.P., Faria, V., Gonçalves, L.M.D., Taboada, P., Remuñán-López, C., Almeida, A.J., Rifabutin-Loaded Solid Lipid Nanoparticles for Inhaled Antitubercular Therapy: physicochemical and in vitro studies. Int. J. Pharm. 497 (2016), 199–209.
171. [171] Paranjpe, M., Neuhaus, V., Finke, J.H., Richter, C., Gothsch, T., Kwade, A., Buttgenbach, S., Braun, A., Muller-Goymann, C.C., In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid nanoparticles. Inhal. Toxicol. 25 (2013), 536–543.
172. [172] Chen, Z., Lai, X., Song, S., Zhu, X., Zhu, J., Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy. Drug Deliv. 23 (2016), 1369–1373.
173. [173] Shi, L.-L., Cao, Y., Zhu, X.-Y., Cui, J.-H., Cao, Q.-R., Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model. Int. J. Pharm. 478 (2015), 60–69.
174. [174] Shah, R.M., Rajasekaran, D., Ludford-Menting, M., Eldridge, D.S., Palombo, E.A., Harding, I.H., Transport of stearic acid-based solid lipid nanoparticles (SLNs) into human epithelial cells. Colloids Surf. B 140 (2016), 204–212.
175. [175] Luigi, B., Marina, G., Elena, P., Daniela, C., Ilaria, S., Susanna, M.A.G., Casimiro, L.G., Chiara, R., Chiara, D., Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies. Nanotechnology, 26, 2015, 255102.
176. [176] Chen, Y., Yang, X., Zhao, L., Almasy, L., Garamus, V.M., Willumeit, R., Zou, A., Preparation and characterization of a nanostructured lipid carrier for a poorly soluble drug. Colloids Surf. A 455 (2014), 36–43.
177. [177] Gaspar, D.P., Faria, V., Gonçalves, L.M.D., Taboada, P., Remuñán-López, C., Almeida, A.J., Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: physicochemical and in vitro studies. Int. J. Pharm. 497 (2016), 199–209.
178. [178] Chen, Z., Lai, X., Song, S., Zhu, X., Zhu, J., Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy. Drug Delivery, 2015, 1–5.
179. [179] Shao, Z., Shao, J., Tan, B., Guan, S., Liu, Z., Zhao, Z., He, F., Zhao, J., Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int. J. Nanomed. 10 (2015), 1223–1233.
180. [180] Tran, T.H., Chu, D.T., Truong, D.H., Tak, J.W., Jeong, J.-H., Hoang, V.L., Yong, C.S., Kim, J.O., Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic. Drug Delivery, 2015, 1–9.
181. [181] Zhao, X.J., Chen, Q., Liu, W., Li, Y.S., Tang, H.B., Liu, X.H., Yang, X.L., Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int. J. Nanomed. 10 (2014), 257–270.